Gates Package — page 251

Members of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Partnership Antonello Punturieri, M.D., Ph.D. Program Director, Division of Lung Diseases National Heart, Lung, and Blood Institute, NIH Srinivas Rao, D.V.M., Ph.D. Global Head, Translational In Vivo Models Global Research Platform Sanofi Jay Rappaport, Ph.D. Professor of Microbiology and Immunology; Director and Chief Academic Officer Tulane University National Primate Research Center Frank Stegmeier, Ph.D. Chief Scientific Officer KSQ Therapeutics John Young, Ph.D. (Co-Chair) Global Head Infectious Diseases and Vice President Roche Roland Zahn, Ph.D. Senior Scientific Director; Head Preclinical Immunology, Viral Vaccines Janssen Vaccines and Prevention Therapeutics Clinical Working Group Neil Aggarwal, M.D. Chief, Lung Biology and Disease Branch National Heart, Lung, and Blood Institute, NIH Samuel Bozzette, M.D., Ph.D. Chief Medical Officer National Center for Advancing Translational Sciences, NIH Jeremy Brown, M.D. Director, Office of Emergency Care Research National Institute of Neurological Disorders and Stroke, NIH Tim Buchman, M.D., Ph.D. IPA Senior Advisor, Division of Research, Innovation and Ventures (DRIVe) Biomedical Advanced Research and Development Authority Captain Timothy Burgess, M.D., M.P.H. Director, Infectious Diseases Clinical Research Program Uniformed Services University of the Health Sciences Joan Butterton, M.D. Associate Vice President, Clinical Research, Infectious Diseases